SUMMIT data for bezuclastinib in NonAdvSM selected for two oral presentations which will describe its best-in-class potentialNovel JAK2 V617F ...

November 03, 2025--(BUSINESS WIRE)--Abcuro, Inc., a late-stage clinical biotechnology company developing potential first-in-class immunotherapies for the ... Monday, December 8, 2025, from 10:30 a.m. ...

Warren Buffett became an investing legend through buying stocks. However, over the past 12 consecutive quarters, he has been a net seller of stocks. The billionaire has sold rough ...

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today ...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech ...

With the shutdown ongoing, Evommune plans to close its IPO on Nov. 5 via a Securities Act clause that allows registrations to ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...

Bristol Myers Squibb is shedding two clinical programs, one from its 2023 Mirati buyout and another from a partnership with U ...

Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing ...

Baron Health Care Fund gained for the quarter and outperformed its benchmark, the Russell 3000 Health Care Index. Read more ...

(KMAland) -- It’s the final week of the regular season for Class 8-Player, A, 1A & 2A. Over the next few days, KMA Sports will break down the playoff scenarios from across the state. We begin with a ...